Biotech News

GRI Bio Participates in Virtual Investor KOL Connect Segment

GRI Bio (GRI)GRI Bio2026-06-25 13:46 ESTCompany update

Albert Agro, PhD, CMO of GRI Bio recently participated in a Virtual Investor KOL Connect segment with prominent key opinion leader in Idiopathic Pulmonary Fibrosis (IPF) - Dr. Helen Parfrey, Respiratory Consultant at the Royal Papworth Hospital and Affiliated Assistant Professor at the University of Cambridge

<p...

Open original release

Related news

GRIGRI Bio2026-06-25 13:46 EST

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

GRIGRI Bio2026-06-25 13:46 EST

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

GRIGRI Bio2026-06-25 13:46 EST

GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GRIGRI Bio2026-06-25 13:46 EST

GRI Bio to Present at the 2024 European Respiratory Congress

GRIGRI Bio2026-06-25 13:46 EST

GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GRIGRI Bio2026-06-25 13:46 EST

GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment

GRIGRI Bio2026-06-25 13:46 EST

GRI Bio Receives Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in Australia

GRIGRI Bio2026-06-25 13:46 EST

GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions

GRIGRI Bio2026-06-25 13:46 EST

GRI Bio to Present at the 22nd International Colloquium on Lung and Airway Fibrosis

GRIGRI Bio2026-06-25 13:46 EST

GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

View all latest news

GRI Bio

GRI Bio is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

GRIGRI Bio2026-06-26 10:46 EST

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

GRIGRI Bio2026-06-26 10:46 EST

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

GRIGRI Bio2026-06-26 10:46 EST

GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GRIGRI Bio2026-06-26 10:46 EST

GRI Bio to Present at the 2024 European Respiratory Congress

GRIGRI Bio2026-06-26 10:46 EST

GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States